CClinicalTrials.gg
Status unknownNCT04511104Updated Aug 14, 2020

Effects of Exercise During the Acute Phase of Burns

A Phase 2 interventional study of Exercise and Standard of Care in Burns, sponsored by Universiteit Antwerpen. Status unknown at 2 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-14.

Sponsored by Universiteit Antwerpen · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2020, registered Aug 2020).
Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

BACKGROUND:

Postburn changes in whole-body, glucose and protein metabolism are at their peak during the acute phase of severe burns. The resulting metabolic derangements lead to substantial muscle wasting, insulin resistance, which ultimately hampers full recovery and reintegration into society.

PURPOSE:

This quasi-experimental trial was initiated to investigate the effects of exercise-based rehabilitation on muscle wasting, insulin resistance, and quality of life during the acute phase of severe adult burns.

METHODS:

Moderate to severely burned adults (10-80%TBSA) will be recruited from two Belgian burn centres.

Subjects allocated to the intervention group will undergo an up to 8-week-long exercise program in addition to standard care rehabilitation. As part of the exercise program, participants will carry out progressive resistance and aerobic training, initiated as soon as medical safety and patient cooperation allow. Exercise type and dosage will be chosen according to patient status in terms of grafts, mobility, and strength.

The control group will receive standard care rehabilitation only, including passive, assisted, active range of motion exercise, functional exercise, and scar treatment.

The effect on muscle wasting will be determined by B-mode ultrasound-derived measures of quadriceps muscle layer thickness (QMLT) and rectus femoris cross sectional area, as well as peak force measurements by handheld dynamometry. Insulin resistance will be derived from the HOMA-2 index based on fasting plasma glucose and insulin. Quality of life will be determined by the EQ-5D-5L and Burn Specific Health Scale-Brief (BSHS-B) questionnaires.

The results of this clinical research will provide insight into the effects of exercise on both a fundamental and clinical spectrum.

Read the detailed description

The added exercise intervention is initiated in line with the following readiness criteria, which will be checked prior to each training session:

Criteria:

  • Mean arterial pressure (MAP) 60 - 110 mmHg
  • Fraction of inspired oxygen (FiO2) \<60%
  • Partial pressure of oxygen / fraction of inspired oxygen (PaO2/FiO2) >200
  • Respiratory rate \<40 bpm
  • Positive end expiratory pressure (PEEP) \<10 cmH2O
  • No high inotropic doses (Dopamine >10 mcg/kg/min or Nor/adrenaline \<0,1 mcg/kg/min)
  • Temp. 36 - 38,5°C
  • Richmond Agitation Sedation Scale (RASS) -2 - +2
  • Medical Doctor clearance
  • Medical research council (MRC) score lower limbs ≥3

Accordingly, the post burn starting time differs per enrolled subject.

Exercises are administered as in-bed exercises or out-of-bed exercises, depending on whether subjects are able and allowed to engage in out-of-bed mobility.

Goal exercise intensity for resistance training is set at 60% peak force based on a weekly peak force measurement by hand-held dynamometry, or on a 3 RM in case of out of bed exercises. Goal aerobic exercise intensity is set at 50-75% peak Watts determined by a weekly cycle ergometer or treadmill ramp protocol.

02

Conditions studied

  • Burns

Browse trials for

Keywords

  • Burns
  • Exercise rehabilitation
  • Exercise Therapy
  • Muscle wasting
  • Hypermetabolism
  • Insulin resistance
03

In context

Burns

719 studies on the registry are indexed under Burns; 145 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 524 interventional studies indexed under Burns.

Browse Burns studies →

Lead sponsor

Universiteit Antwerpen is the lead sponsor of 128 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ≥10 - ≤80 %TBSA
  • Burn depth: 2nd deep / 3rd degree

Exclusion criteria

Exclusion Criteria:

  • Electrical burn (except flash burns)
  • Associated injury: fracture lower limb
  • Diabetes Mellitus type 1
  • Central neurological/neuromuscular disorders (interfering with assessment/exercise)
  • Cognitive / psychological disorders (interfering with cooperation)
  • Cardiopulmonary disease (interfering with exercise safety)
  • Pregnancy
  • Palliative care
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Standard of Care

    Standard of care treatment: - including passive / assisted / active movements, stretching, functional exercise, scar treatment Duration: up to 8 weeks

    Other: Standard of Care

  • Experimental
    Exercise

    Standard of care + added exercises Exercise type: resistance and aerobic exercise Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill) Duration: up to 8 weeks

    Other: Exercise · Other: Standard of Care

Interventions

  • OtherExercise

    Resistance and aerobic exercise in addition to standard of care rehabilitation

  • OtherStandard of Care

    Standard of care rehabilitation

06

What researchers measure

Primary outcomes

  1. Change in quadriceps muscle layer thickness (QMLT)

    Method: B-mode ultrasound on the anterior aspect of the thigh. Technique: maximal and minimal pressure Location: measured at 1/2 and 2/3 of the distance between anterior superior iliac spine and the superior pole of the patella. Analysis: An average of 3 trials will be recorded and analyzed using dedicated software

    Time frame: Baseline - Hospital discharge (max. 8 weeks)

  2. Change in rectus femoris cross sectional area (RF-CSA)

    Method: B-mode ultrasound on the anterior aspect of the thigh. Technique: minimal pressure. Location: measured at the most proximal distance where the entire muscle belly is still visible on the ultrasound image. Analysis: An average of 3 trials will be recorded and analyzed using dedicated software.

    Time frame: Baseline - Hospital discharge (max. 8 weeks)

Secondary outcomes

  1. Change in insulin resistance

    Method: HOMA-2 calculated by fasting plasma glucose and insulin

    Time frame: Baseline - Hospital discharge (max. 8 weeks)

Other outcomes

  1. Change in isometric peak force (knee extension)

    Method: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement. Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials

    Time frame: Baseline - Hospital discharge (max. 8 weeks)

  2. Change in isometric peak force (hip flexion)

    Method: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement. Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials

    Time frame: Baseline - Hospital discharge (max. 8 weeks)

  3. Change in isometric peak force (hip extension)

    Method: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement. Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials

    Time frame: Baseline - Hospital discharge (max. 8 weeks)

  4. Change in hand grip strength

    Method: Baseline LITE hydraulic dynamometer Analysis: Best of 3 trials

    Time frame: Baseline - Hospital discharge (max. 8 weeks)

  5. Change in Burn Specific Health Scale-Brief (BSHS-B)

    Burn-specific quality of life, measured by the Burn Specific Health Scale-Brief questionnaire (Dutch and French language version). Total score 152 (0 worst score, 152 best score), consisting of 6 subdomains: 1) Body imagine (36 points) Simple abilities (36 points) Sexuality (24 points) Affect (32 points) Work (16 points) Interpersonal relationship (8 points)

    Time frame: Baseline - Hospital discharge (max. 8 weeks)

  6. Change in EQ-5D-5L

    Overall quality of life, measured by EQ-5D-5L (Dutch and French language version) Total score: 25 points (0 worst score, 25 best score), consisting of 5 subdomains Mobility (5 points) Self-care (5 points) Usual activities (5 points) pain / discomfort (5 points) Anxiety / Depression (5 points) EQ overall health assessed on a Visual Analogue Scale, Total 0-100 (0 worst, 100 best score)

    Time frame: Baseline - Hospital discharge (max. 8 weeks)

  7. Number of adverse events

    Recording of complications during exercise: Graft take, Wound infections, Medical, Cardio-respiratory safety

    Time frame: Baseline - Hospital discharge (max. 8 weeks)

07

Study locations

2 of 2 sites recruiting
  • Ziekenhuis Netwerk Antwerpen Stuivenberg
    Antwerp, 2060, Belgium
    • Cynthia Lafaire, Dr. · Contact
    • Lieve De Cuyper, Dr. · Contact
    Recruiting
  • Militaire Hospitaal Koningin Astrid, Neder-Over-Heembeek
    Brussels, 1120, Belgium
    • Thomas Rose, Dr. · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Datasets will be made available upon request.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04511104
Lead sponsor
Universiteit Antwerpen
Collaborators
Research Foundation Flanders
Responsible party
Ulrike Van Daele (University professor, Universiteit Antwerpen) — Principal investigator
First posted
Aug 12, 2020
Start date
May 4, 2020
Primary completion
Apr 1, 2022 (estimated)
Completion
Apr 1, 2022 (estimated)
Last update
Aug 14, 2020

Study contacts

David R Schieffelers
Contact
david.schieffelers@uantwerp.be
+3232659177
Ulrike Van Daele
Contact
Ulrike Van Daele
principal investigator · University of Antwerp, Faculty of Medicine and Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion